HTA56 ICER Vs NICE – What Are Your Key Considerations for Health Technology Assessments for Rare Disease Therapies? Insights from a Review of Completed Assessments (2017-PRESENT)
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.1407
https://www.valueinhealthjournal.com/article/S1098-3015(24)01522-5/fulltext
Title :
HTA56 ICER Vs NICE – What Are Your Key Considerations for Health Technology Assessments for Rare Disease Therapies? Insights from a Review of Completed Assessments (2017-PRESENT)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)01522-5&doi=10.1016/j.jval.2024.03.1407
First page :
Section Title :
Open access? :
No
Section Order :
10795